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Abstract
Mammalian target of rapamycin (mTOR) controls lymphangiogenesis. However, the underlying mechanism is not
clear. Here we show that rapamycin suppressed insulin-like growth factor 1 (IGF-1)– or fetal bovine serum (FBS)–
stimulated lymphatic endothelial cell (LEC) tube formation, an in vitro model of lymphangiogenesis. Expression of a
rapamycin-resistant and kinase-activemTOR (S2035T, mTOR-T), but not a rapamycin-resistant and kinase-deadmTOR
(S2035T/D2357E, mTOR-TE), conferred resistance to rapamycin inhibition of LEC tube formation, suggesting that
rapamycin inhibition of LEC tube formation is mTOR kinase activity dependent. Also, rapamycin inhibited proliferation
and motility in the LECs. Furthermore, we found that rapamycin inhibited protein expression of VEGF receptor 3
(VEGFR-3) by inhibiting protein synthesis and promoting protein degradation of VEGFR-3 in the cells. Down-regulation
of VEGFR-3 mimicked the effect of rapamycin, inhibiting IGF-1– or FBS-stimulated tube formation, whereas over-
expression of VEGFR-3 conferred high resistance to rapamycin inhibition of LEC tube formation. The results indicate
that rapamycin inhibits LEC tube formation at least in part by downregulating VEGFR-3 protein expression.
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Introduction
Lymphangiogenesis, like angiogenesis, refers to the formation of
lymphatic vessels from preexisting lymphatic vessels, which plays an
important role in promoting tumor growth and metastasis [1]. For
numerous types of solid tumors, for example, breast, colon, and pros-
tate cancers and melanoma, the lymphatic system is the primary con-
duit for initial metastasis [1,2]. Metastatic cancer spread is enhanced
by an increase of lymphangiogenesis in and around the primary tumor
[1,2]. Clinically, the extent of lymph node metastasis has been regarded
as a major indicator for the staging and the prognosis of most human
cancers and used to determine therapeutic strategy [1]. Thus, targeting
lymphangiogenesis is becoming an attractive and potential approach
for cancer therapy.
The mammalian target of rapamycin (mTOR), a member of the
phosphoinositide-3′ kinase (PI3K)–related kinase family, lies down-
stream of the insulin-like growth factor 1 (IGF-1) receptor–PI3K
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[3,4]. mTOR functions at least as two complexes (mTORC1 and
mTORC2) in mammalian cells [3,4]. mTORC1 is composed of
mTOR, mLST8 (also termed G-protein β-subunit–like protein, a
yeast homolog of LST8), proline-rich Akt substrate 40 kDa, and raptor
(regulatory-associated protein of mTOR) [5–11], whereas mTORC2
consists of mTOR, mLST8, mammalian stress-activated protein
kinase-interacting protein 1, rictor (rapamycin-insensitive companion
of mTOR), and protor (protein observed with rictor, also named
proline-rich protein 5) [12–19]. mTORC1 is sensitive to rapamycin,
growth factors, energy, amino acids, and redox levels and phosphory-
lates ribosomal p70 S6 kinase 1 (S6K1) and eukaryotic initiation
factor 4E binding protein 1 (4E-BP1) [5–11]. mTORC2 is only sen-
sitive to prolonged (>24 hours) rapamycin exposure in certain cases and
growth factors and phosphorylates Akt and serum and glucocorticoid-
inducible kinase 1 [12–20]. In response to growth factors, energy,
amino acids, and redox levels, mTORC1 regulates cell proliferation
and growth by controlling protein synthesis and ribosome biogenesis
through phosphorylation of 4E-BP1 and S6K1 [5–11]. Both mTORC1
and mTORC2 interact with a negative regulator DEPTOR [21]. Al-
though the cellular functions of the mTOR complexes remain to be
determined, current data indicate that mTOR plays a central role in the
regulation of cell growth, proliferation, survival, differentiation, motility,
and angiogenesis [3,4].
Clinical trials have demonstrated that rapamycin and its analogs
(CCI-779, RAD001, and AP23573; termed rapalogs) are promising
anticancer agents. Rapalogs share a common mechanism by which
they form a complex with FK506 binding protein 12 and then bind
to mTOR, selectively inhibiting its function [22]. Studies have demon-
strated that rapamycin functions as an anticancer agent by inhibiting
cell growth and proliferation, inducing apoptosis and autophagy, in-
hibiting cell motility and invasion, and preventing angiogenesis [22].
Recently, rapamycin has been found to exert a potent antilymphangio-
genic effect in vitro and in vivo [23–25], suggesting that mTOR regulates
lymphangiogenesis as well. However, so far, the underlying molecular
mechanism remains largely unknown.
Vascular endothelial growth factor (VEGF) receptor 3 (VEGFR-3), also
known as fms-like tyrosine kinase 4, is primarily expressed on the surface
of the lymphatic endothelial cells (LECs) [26]. In response to VEGF-C/D
binding, VEGFR-3 can be activated, leading to activation of the down-
stream signaling molecules, such as PI3K/Akt and mitogen-activated
protein kinase pathways, which are crucial for LEC survival and lymphan-
giogenesis [27–30], as well as metastasis [1,2,31]. Thus, VEGFR-3 path-
way has emerged as a novel target for cancer prevention and treatment.
Deregulation of IGF-1 signaling occurs frequently in a variety of
tumors, and is correlated to malignant progression and poor prognosis
[3,4]. Recent studies have demonstrated that IGF-1 and IGF-2 also
induce lymphangiogenesis in vitro and in vivo [32,33], suggesting that
IGFs may contribute to tumor lymphangiogenesis and lymphatic
metastasis. Here, for the first time, we show that mTOR regulates
IGF-1– or fetal bovine serum (FBS)–stimulated lymphangiogenesis
in an in vitromodel (tube formation) [34] by mediating protein expres-
sion of VEGFR-3, further highlighting that mTOR inhibitors can be
exploited for prevention and treatment of tumor metastasis.
Materials and Methods
Cell Lines and Cultures
Mouse LECs and pleural mesothelial cells (MIM), derived from the
mesenteric lymphatic tissue and the pleura of transgenic mice expres-
sing SV40 large T antigen [35], respectively, were grown in antibiotic-
free Dulbecco modified Eagle medium (DMEM)/F12 medium
(Mediatech, Herndon, VA) supplemented with 10% FBS (HyClone,
Logan, UT) at 37°C and 5% CO2. Human embryonic kidney 293
(American Type Culture Collection, Manassas, VA) and 293TD cells
(Invitrogen, Carlsbad, CA) were grown in antibiotic-free DMEM
supplemented with 10% heat-inactivated FBS at 37°C and 5% CO2.
For experiments where cells were deprived of serum, cell monolayers
were washed with phosphate-buffered saline, and incubated in the
serum-free DMEM/F12 medium (Mediatech).
Plasmids and Transfection
LEC clones stably overexpressing p3×Flag-VEGFR-3-TV1 and
p3×Flag-TV1 plasmid (empty vector, as a control) were generated
and used as described [34].
Recombinant Adenoviral Constructs and Infection
The recombinant adenoviruses expressing FLAG-tagged rapamycin-
resistant and kinase-active mTOR (S2035T, designated mTOR-T),
rapamycin-resistant and kinase-dead mTOR-T (S2035T/D2357E,
designated mTOR-TE) and the control vector expressing green fluo-
rescence protein (GFP) alone (Ad-GFP) were described previously
[37]. All recombinant adenoviral constructs were amplified, titrated,
and used as described [37].
Lentiviral Short Hairpin RNA Cloning, Production,
and Infection
Lentiviral short hairpin RNAs (shRNAs) to VEGFR-3 and GFP
were produced as described [34]. LECs, when grown to ∼70% conflu-
ence, were infected with the above lentiviral shRNAs in the presence
of 8 μg/ml polybrene and exposed to 2 μg/ml puromycin after 24 hours
of infection. In 5 days, cells were used for experiments.
Tube Formation Assay
Tube formation assay was performed as described [34]. Briefly,
LECs, pretreated with or without rapamycin (100 ng/ml) for 24 hours,
in the presence or absence of IGF-1 (10 ng/ml) or 2% FBS, were tryp-
sinized and then seeded into a 96-well plate (2 × 104/well) precoated
with 40 μl (10 mg/ml) growth factor–reduced Matrigel (BD Bio-
sciences, Billerica, MA), in DMEM/F12 medium supplemented
with/without rapamycin (100 ng/ml) ± IGF-1 (10 ng/ml) or 2%
FBS. After 2 to 3 hours of incubation at 37°C, the capillary tube struc-
tures were observed, and representative images were captured with an
Olympus inverted phase-contrast microscope (Olympus Optical Co,
Melville, NY) (200×) equipped with the Quick Imaging system. Tube
length was quantified by ImageJ software (http://rsbweb.nih.gov/ij/;
National Institutes of Health, Bethesda, MD). Briefly, three randomly
selected fields of view were photographed in each treatment. Tube
length was assessed by drawing a line along each tube and measuring
the length of the line in pixels. The average of three fields was taken as
the value for each treatment.
Assays for Cell Proliferation, Cell Motility, and Viability
The effects of rapamycin on LEC proliferation, motility, and via-
bility were determined as described previously, using cell prolifera-
tion assay [36], single-cell motility assay [37], and one-solution assay
[38], respectively.
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Reverse Transcription–Polymerase Chain Reaction
The effect of rapamycin on VEGFR-3 mRNA expression was de-
termined by semiquantitative reverse transcription–polymerase chain
reaction (RT-PCR), as described [34].
Determination of VEGFR-3 Protein Synthesis
and Degradation
To determine the effect of rapamycin on VEGFR-3 protein syn-
thesis, LECs, grown in 100-mm dishes to 70% confluence, were
serum starved for 24 hours, and pretreated with or without rapamycin
(100 ng/ml) for 22 hours, followed by stimulation with IGF-1 (10 ng/
ml) or 2% FBS for 2 hours. Subsequently, the cells were briefly washed
with phosphate-buffered saline twice and cultured in 3 ml of label-
ing medium (DMEM, without L-Met/L-Cys; Mediatech) containing
10 μM MG-132 for 10 minutes to deplete Met/Cys in the cells,
in the presence or absence of rapamycin with or without IGF-1 or
FBS. The cells were then pulsed with 0.3 mCi of 35S-Met/Cys (MP
Biomedicals, Solon, OH) for 4 hours and lysed in the RIPA buffer
(50 mM Tris, pH 7.2, 150 mM NaCl, 1% sodium deoxycholate,
0.1% SDS, 1% Triton X-100, 10 mMNaF, 1 mMNa3VO4, protease
inhibitor cocktail [1:1000; Sigma, St Louis, MO]) followed by immuno-
precipitation with antibodies to VEGFR-3 and GAPDH, respectively.
The immunocomplexes were subjected to SDS-PAGE, transferred to a
polyvinylidene fluoride membrane, and finally autoradiographed at
−80°C. ImageJ was used to semiquantitate the intensities of the bands.
To determine the effect of rapamycin on VEGFR-3 protein degra-
dation, LECs, grown in the growth medium to 90% confluence, were
treated with 50 μg/ml cycloheximide (CHX; Sigma) in the presence
or absence of rapamycin (100 ng/ml) for 0 to 12 hours, followed by
Western blot analysis with antibodies to VEGFR-3 and β-tubulin
(loading control), respectively.
Western Blot Analysis
Western blot analysis was performed as described previously [34].
The primary antibodies used included antibodies to mTOR (FRAP),
S6K1, LYVE-1, fms-like tyrosine kinase 4 (VEGFR-3), GAPDH
(Santa Cruz Biotechnology, Santa Cruz, CA), 4E-BP1 (Zymed Lab-
oratories, South San Francisco, CA), p-S6K1 (T389), p-4E-BP1
(T70) (Cell Signaling, Beverly, MA), FLAG, and β-tubulin (Sigma).
ImageJ was used to semiquantitate the intensities of the bands.
Statistical Analysis
Results were expressed as mean values ± SD. Data were analyzed
by one-way analysis of variance followed by post hoc Dunnett t test
for multiple comparisons. P < .05 was considered significant.
Results
Rapamycin Inhibits IGF-1– or FBS-Stimulated Tube
Formation in LECs
To elucidate the molecular mechanism by which mTOR regulates
lymphangiogenesis, first of all, we investigated the effect of rapamycin,
a selective inhibitor of mTOR, on capillary-like tube formation in
LECs, an in vitro lymphangiogenesis model [34]. Two established
LEC lines, LEC and MIM [35], were used. As shown in Figure 1A,
a lymphatic specific marker, LYVE-1, was detectable in LEC and
MIM cells, but not in a rhabdomyosarcoma (Rh30) cells (as a negative
control), indicating that both LEC and MIM still possessed lymphatic
characteristics through passages and could be used for the studies. We
found that serum-starved LEC and MIM cells hardly formed the
capillary tube structures on growth factor–reduced Matrigel within
2 hours (Figure 1B). Consistent with the previous in vivo findings
[32,33], IGF-1 did stimulate lymphangiogenesis in vitro, as detected
by the tube formation (Figure 1B). Here we found that IGF-1 (10 ng/
ml) or 2% FBS stimulated the tube formation by approximately five-
to seven-fold, which was significantly attenuated by pretreatment with
rapamycin (100 ng/ml, for 24 hours; Figure 1C ).
Because cell proliferation and migration are critical steps for lymphan-
giogenesis [1,2], we also examined the effects of rapamycin on these
cellular events. As illustrated in Figure 2A, treatment with rapamycin
for 72 hours inhibited proliferation in LECs in DMEM/F12 or the
medium supplemented with IGF-1 (10/ng/ml) or FBS (10%) in a
concentration-dependent manner. The half maximal inhibitory con-
centration (IC50) was 20 to 30 ng/ml. In addition, IGF-1 or 2% FBS
stimulated LEC motility by approximately three- to four-fold, which
was attenuated by rapamycin (100 ng/ml) nearly to the basal level
(Figure 2B). However, treatment with rapamycin (100 ng/ml) for
24 hours did not obviously alter cell viability (Figure 2C), as detected
by one-solution assay. Considering that one-solution assay cannot differ-
entiate cell proliferation inhibition from cytotoxicity, trypan blue stain-
ing, a conventional method to detect cell viability, was used. We noticed
that treatment with rapamycin (100 ng/ml) for 24 hours did not have
an obvious effect on the cell viability in LEC and MIM cells, as approxi-
mately 96% of the cells excluded the dye.
Rapamycin Inhibits IGF-1– or FBS-Stimulated LEC Tube
Formation in an mTOR Kinase Activity–Dependent Manner
Because a kinase activity–independent function for mTOR in the
regulation of cell differentiation has been reported [39], we next exam-
ined whether rapamycin inhibits LEC tube formation by inhibiting
the kinase activity of mTOR. For this, LECs were infected with re-
combinant adenovirus expressing empty vector (GFP), FLAG-tagged
rapamycin-resistant but kinase-active mTOR (S2035T, mTOR-T), or
kinase-dead mTOR-T (S2035T/D2357E, mTOR-TE) for 24 hours,
and then treated with or without rapamycin for 24 hours in the presence
or absence of IGF-1 or 2% FBS. We found that the expression of
mTOR-T, but not mTOR-TE or GFP, prevented rapamycin inhibi-
tion of phosphorylation of S6K1 (T389) and 4E-BP1 (Figure 3A), the
two best-characterized downstream effector molecules of mTOR. The
results show that mTOR-T functioned as a rapamycin-resistant mutant,
and mTOR-TE as a kinase-dead mutant in LECs, as seen in other cell
lines [37]. Interestingly, expression of mTOR-T, but not mTOR-TE
or GFP, conferred high resistance to rapamycin inhibition of LEC tube
formation (Figure 3B), suggesting that rapamycin inhibits IGF-1– or
FBS-stimulated LEC tube formation in an mTOR kinase activity–
dependent manner.
Rapamycin Inhibits Expression of VEGFR-3
Protein Expression
VEGFR-3 is primarily expressed in LECs and essential for lymphan-
giogenesis [1,26]. To determine whether mTOR regulates lymphan-
giogenesis through targeting VEGFR-3 signaling, LECs were exposed
to rapamycin (100 ng/ml) for 24 hours, followed byWestern blot analy-
sis. As shown in Figure 4A, a considerable level of cellular VEGFR-3
protein was detectable in LECs grown in serum-free DMEM/F12
medium, and IGF-1 (10 ng/ml) or 2% FBS stimulated VEGFR-3 ex-
pression by approximately two- to three-fold. As expected, rapamycin
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treatment inhibited the basal or IGF-1/FBS–stimulated phosphory-
lation of S6K1 and 4E-BP1, two best-known substrates of mTOR
[3,4]. Of interest, rapamycin downregulated the basal or IGF-1/FBS–
stimulated expression of VEGFR-3 by more than 85%, suggesting that
mTOR regulates VEGFR-3 protein expression.
To substantiate the above finding, LECs were ectopically express-
ing mTOR-T and GFP, respectively, by infection with corresponding
recombinant adenoviruses. As shown in Figure 4B, expression of
mTOR-T, but not GFP, prevented rapamycin down-regulation of
VEGFR-3 expression, indicating that rapamycin inhibits VEGFR-3
protein expression in an mTOR-dependent manner.
Rapamycin Inhibits LEC Tube Formation by Downregulating
VEGFR-3 Protein Expression
To determine the role of VEGFR-3 in rapamycin inhibition of LEC
tube formation, LECs (LEC/VEGFR-3) stably overexpressing VEGFR-3
were generated. In comparison with the control cells (LEC/V) transfected
with the empty vector, an approximately three-fold increase of VEGFR-3
protein expressionwas detected in LEC/VEGFR-3 cells (Figure 5A, upper
panel ). Treatment with rapamycin (100 ng/ml) for 24 hours reduced the
basal or IGF-1/FBS–stimulated protein expression of VEGFR-3 by
approximately 85% in LEC/V cells (Figure 5A, bottom panel ). When
LEC/VEGFR-3 cells were treated with rapamycin (100 ng/ml) for
Figure 1. Rapamycin inhibits IGF-1/FBS–stimulated tube formation in LECs. (A) Cell lysates from indicated cells were subjected to Western
blot analysis with the indicated antibodies. (B and C) LEC and MIM cells were treated with rapamycin (Rapa, 100 ng/ml) for 24 hours, in the
presence or absence of IGF-1 (10 ng/ml) or 2% FBS, followed by tube formation assay. Representative images are shown in B. Bar, 100 μm.
The length of tube-like formation was evaluated by ImageJ software. Quantitative data are presented as mean ± SD (n = 3) in C. aP < .05,
difference versus control group. bP < .05, difference versus IGF-1 group. cP < .05, difference versus FBS group.
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24 hours, VEGFR-3 protein expression was downregulated by 70%,
50%, and 30% under serum-free, IGF-1, and FBS stimulation condi-
tions, respectively, but the VEGFR-3 protein levels under any condi-
tions were still higher than the basal level in the control (LEC/V) cells
(Figure 5A, bottom panel ). Of interest, overexpression of VEGFR-3 did
not significantly influence the basal tube formation, but significantly
increased IGF-1/FBS–stimulated tube formation and conferred high
resistance to rapamycin inhibition of the tube formation in LECs
(Figure 5B), suggesting that rapamycin inhibits LEC tube formation
at least in part by suppressing VEGFR-3 protein expression.
To further verify the role of VEGFR-3 in rapamycin inhibition of
LEC tube formation, we used RNA interference. Infection with lenti-
viral shRNA to VEGFR-3 knocked down the protein expression of
VEGFR-3 by approximately 90%, comparing with the control infected
with lentiviral shRNA to GFP (Figure 5C , upper panel ). Silencing
VEGFR-3 mimicked the effect of rapamycin, inhibiting IGF-1– or
FBS-stimulated tube formation by approximately 80% (Figure 5D).
Under this condition, no synergistic or additive inhibitory effect on
the tube formation was observed by treatment with rapamycin (Fig-
ure 5D). The results suggest that rapamycin inhibits LEC tube forma-
tion primarily by suppressing VEGFR-3 protein expression.
In addition, we also observed that silencing VEGFR-3 inhibited
FBS- or IGF-1–stimulated tube formation in LECs infected with re-
combinant adenoviral vectors expressing mTOR-T or GFP (control),
regardless of the presence or absence of rapamycin (data not shown).
The result indicates that silencing VEGFR-3 was able to overcome
the resistance of cells expressing mTOR-T to inhibition of tube forma-
tion by rapamycin. However, when LEC/VEGFR-3 cells were infected
with recombinant adenoviral vectors expressing mTOR-TE or GFP
(control), considerable levels of VEGFR-3 were still detected in the cells
stimulated with IGF-1– or FBS (Figure 5E), which was in agreement
with the observation in LEC/VEGFR-3 cells (Figure 5A). Of note,
overexpression of VEGFR-3 rendered high resistance to rapamycin in-
hibition of IGF-1– or FBS-stimulated tube formation in LECs expres-
sing mTOT-TE or GFP (Figure 5F ). Our findings strongly suggest
that VEGFR-3 is essential for mTOR-mediated LEC tube formation.
Rapamycin Inhibits Protein Expression of VEGFR-3
by Inhibiting Protein Synthesis and Promoting
Protein Degradation of VEGFR-3 in LECs
Rapamycin inhibition of protein expression of VEGFR-3 may
occur at transcriptional, translational, and/or posttranslational level.
To address this question, firstly, semiquantitative RT-PCR was used
to determine whether rapamycin affects VEGFR-3 mRNA expression.
As shown in Figure 6A, stimulation with IGF-1 (10 ng/ml) or 2% FBS
in the presence or absence of rapamycin (100 ng/ml, 24 hours) did not
significantly alter mRNA expression of VEGFR-3.
Next, 35S-Met/Cys labeling was used to determine whether rapamycin
affects VEGFR-3 protein synthesis. Serum-starved LECs were pre-
treated with IGF-1 (10 ng/ml) or 2% FBS in the presence or absence
of rapamycin (100 ng/ml) for 24 hours and then pulsed with 35S-Met/
Cys for 4 hours. By autoradiography, IGF-1 or FBS enhanced
Figure 2. Rapamycin inhibits proliferation and motility in LECs. (A) LECs, grown in serum-free DMEM/F12 or the medium supplemented
with IGF-1 (10 ng/ml) or FBS (10%), were exposed to rapamycin (0-1000 ng/ml) for 72 hours, followed by cell counting using a Beckman
Coulter counter. (B) Cell motility of LECs was determined using the single-cell motility assay. (C) LEC viability was evaluated by one-solution
assay. Quantitative data are presented as mean ± SD (n = 3) in A to C. aP < .05, difference versus control group. bP < .05, difference
versus IGF-1 group. cP < .05, difference versus FBS group.
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incorporation of 35S-Met/Cys into VEGFR-3 by approximately 1.5-fold,
which was significantly (by 40%-45%) attenuated by rapamycin
(Figure 6B), suggesting that rapamycin inhibits protein synthesis of
VEGFR-3 in LECs.
In addition, to determine whether rapamycin influences protein
degradation of VEGFR-3, LECs, grown in the complete growth me-
dium, were exposed to CHX (50 μg/ml), an inhibitor of eukaryotic
protein synthesis by preventing initiation and elongation on 80S ribo-
somes, in the presence or absence of rapamycin (100 ng/ml), for up to
12 hours, followed by Western blot analysis. We found that rapamycin
strikingly promoted VEGFR-3 protein turnover rate. As shown in
Figure 6C , a considerable level of VEGFR-3 protein was still detect-
able when the cells were treated with CHX alone for 8 hours. How-
ever, a lower level of VEGFR-3 protein was observed when the cells
were treated with CHX + rapamycin only for 4 hours. Taken together,
our results reveal that rapamycin did not alter the mRNA level, but
inhibited the protein synthesis and promoted the protein degradation
of VEGFR-3, thereby downregulating VEGFR-3 protein expression
in LECs.
Discussion
Recent studies have shown that mTOR not only controls angio-
genesis [40,41] but also regulates lymphangiogenesis [23–25]. mTOR
controls angiogenesis by regulating expression of hypoxia-inducible
Figure 3. Rapamycin inhibits LEC tube formation in an mTOR kinase activity–dependent manner. LECs were infected for 24 hours with
Ad-GFP, Ad-mTOR-T, and Ad-mTOR-TE, respectively, and then serum-starved for 24 hours. Subsequently, the cells were treated with
or without rapamycin (Rapa, 100 ng/ml) for 24 hours, in the presence or absence of IGF-1 (10 ng/ml) or 2% FBS, followed by Western
blot analysis with the indicated antibodies (A) or tube formation assay (B). Quantitative data are presented as mean ± SD (n = 3) in B.
aP < .05, difference versus control group. bP < .05, difference versus IGF-1 group. cP < .05, difference versus FBS group.
Figure 4. Rapamycin inhibits cellular protein expression of VEGFR-3
in LECs. LECs (A), or LECs infected for 24 hours with Ad-GFP and
Ad-mTOR-T, respectively (B), were treated with rapamycin (Rapa,
100 ng/ml) for 24 hours, in the presence or absence of IGF-1 (10 ng/
ml) or 2% FBS, followed by Western blot analysis with the indicated
antibodies. β-Tubulin was used as a loading control.
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Figure 5. Rapamycin inhibits LEC tube formation by downregulating VEGFR-3 protein expression. (A and B) Overexpression of VEGFR-3
confers high resistance to rapamycin inhibition of LEC tube formation. Overexpression of VEGFR-3 was detected in pooled clones of LECs
stably transfected VEGFR-3 (LEC/VEGFR-3) but not in the control cells transfected with an empty vector (LEC/V) by Western blot analysis
(A, upper panel). LEC/V (control) and LEC/VEGFR-3 cells were treated with rapamycin (Rapa, 100 ng/ml) for 24 hours, in the presence or
absence of IGF-1 (10 ng/ml) or 2% FBS, followed byWestern blot analysis with the indicated antibodies (A, bottom panel) or tube formation
assay (B). Quantitative results of tube formation are shown as mean ± SD (n= 3) in (B). aP< .05, difference versus control group. bP< .05,
difference versus LEC/V group. cP < .05, difference versus IGF-1 group. dP < .05, difference versus FBS group. (C and D) Down-regulation
of VEGFR-3 mimics the effect of rapamycin, inhibiting IGF-1/FBS–stimulated tube formation. Lentiviral shRNA to VEGFR-3, but not GFP,
downregulated VEGFR-3 protein expression in LECs, as detected by Western blot analysis with the indicated antibodies (C, upper panel).
LECs, infected with lentiviral shRNAs to VEGFR-3 and GFP (control), respectively, were treated with rapamycin (Rapa, 100 ng/ml) for
24 hours, in the presence or absence of IGF-1 (10 ng/ml) or 2% FBS, followed by Western blot analysis with the indicated antibodies
(C, bottom panel) or tube formation assay (D). Quantitative results of tube formation are shown as mean ± SD (n = 3) in D. aP < .05,
difference versus control group. bP< .05, difference versus GFP shRNA group. cP< .05, difference versus IGF-1 group. dP< .05, difference
versus FBS group. (E and F) Overexpression of VEGFR-3 renders high resistance to rapamycin inhibition of tube formation in LECs expres-
sing mTOR-TE. LEC/VEGFR-3 cells were infected for 24 hours with Ad-GFP and Ad-mTOR-TE, respectively, and then serum starved for
24 hours. Subsequently, the cells were treated with or without rapamycin (Rapa, 100 ng/ml) for 24 hours, in the presence or absence of
IGF-1 (10 ng/ml) or 2% FBS, followed by Western blot analysis with the indicated antibodies (E) or tube formation assay (F). Quantitative
data are presented as mean ± SD (n = 3) in F. aP < .05, difference versus control group.
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factor 1α and VEGF-A (or VEGF) [40,41]. However, it is not known
how mTOR regulates lymphangiogenesis. Here, for the first time,
we present evidence that mTOR regulates IGF-1– or FBS-stimulated
lymphangiogenesis in an in vitro model (tube formation) by mediating
the expression of VEGFR-3 in LECs. This is supported by the obser-
vations that 1) rapamycin inhibits IGF-1– or FBS-stimulated LEC
tube formation in an mTOR kinase activity–dependent manner; 2)
rapamycin inhibited IGF-1– or FBS-stimulated VEGFR-3 protein
expression; 3) overexpression of VEGFR-3 conferred high resistance
to rapamycin inhibition of IGF-1– or FBS-stimulated LEC tube for-
mation; and 4) down-regulation of VEGFR-3 mimicked the effect
of rapamycin, blocking IGF-1– or FBS-stimulated LEC tube forma-
tion. These data are in line with the previous findings that block-
ing VEGFR-3 signaling alone by VEGFR-3 fusion protein [42,43],
VEGFR-3–soluble form [29,44], or small-molecule inhibitors of
VEGFR-3 [30,45,46] inhibited lymphangiogenesis. As deregulation
of IGF-1 signaling occurs frequently in a variety of tumors and is
associated with malignant progression and poor prognosis [3,4], our
results strongly support the notion that mTOR inhibitors are a new
class of antilymphangiogenic agents and that they may be explored
for prevention and treatment of tumor metastasis.
VEGFs and their receptors are central controllers of angiogenesis
and lymphangiogenesis [1]. Five VEGFs (VEGF or VEGF-A, placenta
growth factor, VEGF-B, VEGF-C, and VEGF-D) and three VEGF
Figure 6. Rapamycin does not alter mRNA expression but inhibits protein synthesis and promotes protein degradation of VEGFR-3.
(A) Rapamycin did not affect VEGFR-3 mRNA level. Total RNA was extracted from LECs treated with rapamycin (Rapa, 100 ng/ml) for
24 hours in the presence or absence of IGF-1 (10 ng/ml) or 2% FBS, followed by semiquantitative RT-PCR. β-Actin was used as a loading
control. (B) Rapamycin inhibited protein synthesis of VEGFR-3 in LECs. LECs were pretreated with rapamycin (Rapa, 100 ng/ml) for
24 hours, in the presence or absence of IGF-1 (10 ng/ml) or 2% FBS, and then pulsed with 35S-Met/Cys for 4 hours, followed by immuno-
precipitation with antibodies to VEGFR-3. The immunoprecipitates were separated by SDS-PAGE and transferred to polyvinylidene fluoride
membranes, followed by autoradiography. GAPDH served as an internal control. (C) Rapamycin promoted protein degradation of VEGFR-3
in LECs. LECs, grown in 10% FBS-DMEM/F12 medium, were exposed to CHX (50 μg/ml), in the presence or absence of rapamycin (Rapa,
100 ng/ml) for 0 to 12 hours, followed by Western blot analysis with the indicated antibodies. Semiquantitative data for A, B, and C by
densitometry using ImageJ are shown in D, E, and F, respectively. Results are means ± SD and are pooled from three independent
experiments. aP < .05, difference versus control group. bP < .05, difference versus IGF-1 group. cP < .05, difference versus FBS group.
dP < .05, difference versus CHX group.
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receptors (VEGFR-1, -2, and -3) have been well documented in
mammals [1]. VEGFR-1/2 and VEGFR-3 are primarily expressed on
the surface of vascular and LECs, respectively [1]. VEGF-A binds to
VEGFR-1/2, regulating vasculogenesis and angiogenesis, whereas
VEGF-C/D binds to VEGFR-3, mediating lymphangiogenesis [1]. It
has been described that rapamycin inhibits lymphangiogenesis by
inhibiting expression of VEGF-C in rat lymphatic metastasis-prone cell
line B13LM, a tumor cell line [24]. However, in the present study, we
failed to detect expression of VEGF-C or -D in immortalized murine
LECs, which were isolated from the mesenteric lymphatic tissue of
transgenic mice expressing SV40 large T antigen [35], even without
rapamycin treatment (data not shown). As a positive control, we did ob-
serve that rapamycin downregulated protein expression of VEGF-C in
prostate (PC-3) and breast (MDA-MB231) carcinoma cells (data
not shown). Our data are in agreement with the previous findings
that VEGFs are generally produced and secreted by tumor cells but
not by the vascular or LECs [1,2]. The results further indicate that
rapamycin inhibition of IGF-1– or FBS-stimulated LEC tube forma-
tion in our model was primarily through blocking VEGFR-3 protein
expression rather than through inhibiting VEGF-C/D expression.
However, we also found that overexpression of VEGFR-3 alone was
not able to induce LEC tube formation under serum starvation with-
out stimulation with IGF-1 or FBS, suggesting that a certain level of
VEGFR-3 activity in the cells is essential for the tube formation. Also,
FBS seemed to stimulate LEC tube formation more potently than
IGF-1. This is probably due to the presence of more growth factors
(platelet-derived growth factors [PDGFs], fibroblast growth factor 2,
IGFs, etc.) or hormones (e.g., insulin) in the FBS. In addition, we
noticed that overexpression of VEGFR-3 failed to completely rescue
the tube formation inhibited by rapamycin, suggesting that rapamycin
inhibits IGF-1– or FBS-stimulated LEC tube formation probably
involving other signaling molecules as well. More studies are needed
to address this issue.
In addition to VEGF-C/D, several growth factors have also been
reported to induce lymphangiogenesis [32,33,47–51]. However, the
mechanisms underlying these effects are various among the growth
factors. For instance, the basic fibroblast growth factor 2 induced
lymphatic vessel growth in the mouse cornea, which occurred indirectly
by induction of VEGF-C expression and activation of VEGFR-3 sig-
naling [47,48]. PDGF-BB or hepatocyte growth factor promoted
lymphangiogenesis, through direct activation of hepatocyte growth
factor receptor (also known as c-Met) or PDGF receptors, respectively,
rather than through activation of VEGFR-3 [49,50]. Similarly, IGF-1
induced lymphangiogenesis by direct activation of IGF-1 receptor,
which was independent of VEGF-C/-D/VEGFR-3 system as well, be-
cause a soluble VEGFR-3, a known lymphangiogenic antagonist, was
unable to block IGF-1–induced corneal angiogenesis or lymphangio-
genesis in vivo [32]. In this study, however, we found that IGF-1 stimu-
lates LEC tube formation through up-regulation of VEGFR-3 protein
expression, which is regulated through an mTOR-dependent mecha-
nism. It has been described that IGF-1 induces angiogenesis by indirect
up-regulation of VEGF expression [51], implying dependence on
VEGFR signaling. Although we cannot rule out the discrepancy being
due to different experimental models used, likely, IGF-1 may regulate
angiogenesis and lymphangiogenesis through VEGFR-dependent and
-independent mechanisms. Further studies are required to determine
how IGF-1 activates VEGFR-3 signaling.
In this study, we found that rapamycin dramatically decreased the
basal or IGF-1/FBS–stimulated VEGFR-3 expression in LECs. To
understand the underlying mechanism, RT-PCR, 35S-Met/Cys
labeling, and VEGFR-3 protein degradation assay were performed.
We found that IGF-1, FBS, or rapamycin did not obviously alter
VEGFR-3 mRNA level. However, rapamycin was able to inhibit
protein synthesis and promote protein degradation of VEGFR-3.
This is in agreement with other observations that mTOR mediates
Cap-dependent translation initiation of cyclin D1, VEGF, and others
[3–5]. Currently, we do not know how rapamycin promotes VEGFR-3
degradation. Most recent studies have demonstrated that mTOR regu-
lates DEPTOR protein level through SCF(βTrCP) E3 ubiquitin ligase–
dependent mechanism [52–54]. New studies may gain insight into
whether rapamycin downregulates VEGFR-3 by a similar mechanism.
In summary, here we have shown that rapamycin inhibits IGF-1/
FBS–stimulated LEC tube formation in an mTOR kinase activity–
dependent manner, supporting the idea that mTOR regulates lymphan-
giogenesis. Mechanistically, rapamycin inhibits LEC tube formation
at least in part through downregulating VEGFR-3 protein expression.
The results suggest that mTOR inhibitors are potent antilymphan-
giogenic agents and that they can be explored for the prevention and
treatment of tumor metastasis.
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